Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Journal: European urology
Published: June 24, 2014
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 20, 2012
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Journal: Journal of medical economics
Published: March 14, 2012
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Journal: Journal of managed care pharmacy : JMCP
Published: January 13, 2012
Showing 1-4 of 4
Last Updated: 09/26/2026